The Benefits and Side Effects of Bevacizumab for the Treatment of Recurrent Ovarian Cancer

Title:The Benefits and Side Effects of Bevacizumab for the Treatment of Recurrent Ovarian Cancer

Volume: 18 Issue: 10

Author(s): Wenwen Zhang, Zhaojun Shen, Hui Luo, Xiaoli Hu, Lihong Zheng and Xueqiong Zhu*

Affiliation:

• Department of Obstetrics and Gynecology, the Second Affiliated Hospital of Wenzhou Medical University, No. 109 Xueyuan Xi Road, Wenzhou, Zhejiang 325027,China

Keywords: Bevacizumab, chemotherapy, efficacy, ovarian cancer, recurrent, safety, chemotherapy.

Abstract: Background: Ovarian cancer is the leading cause of deaths attributable to gynecologic malignancies. Late diagnosis and a high tendency of metastasis and drug resistance often lead to recurrence and poor outcomes. Anti-angiogenesis is considered a promising therapeutic strategy for recurrent ovarian cancers. Anti-VEGF body, bevacizumab, is an angiogenesis inhibitor with demonstrated activity and tolerable toxicity.

Objective: To elucidate the benefits and side effects of bevacizumab for the therapy of recurrent ovarian cancer.

Methods: Reviewed the results of published clinical trials.

Results: Recent Phase II studies indicated that bevacizumab monotherapy or in combination with conventional or other anti-angiogenic chemotherapy reagents could be effective for recurrent (platinum- sensitive and -resistant) ovarian cancers. Additionally, two phase III randomized trials reached similar conclusions that in either platinum-sensitive or -resistant ovarian cancers, adding bevacizumab to chemotherapy can improve progression-free survival. Despite the general recognition of bevacizumab as a well-tolerated drug in recurrent ovarian cancer patients, oncologists have become aware of the significant risks associated with gastrointestinal perforation.

Conclusion: Bevacizumab used alone or combined with other chemotherapy reagents is efficacious and tolerable in the treatment of recurrent ovarian cancer.

Cite this article as:

Zhang Wenwen, Shen Zhaojun, Luo Hui, Hu Xiaoli, Zheng Lihong and Zhu Xueqiong*, The Benefits and Side Effects of Bevacizumab for the Treatment of Recurrent Ovarian Cancer, Current Drug Targets 2017; 18 (10) . https://dx.doi.org/10.2174/1389450117666160502150237

DOI https://dx.doi.org/10.2174/1389450117666160502150237	Print ISSN 1389-4501
Publisher Name Bentham Science Publisher	Online ISSN 1873-5592